Literature DB >> 6401365

Osteoporosis in the rheumatoid hand--the effects of treatment with D-penicillamine and oral gold salts.

D Schorn.   

Abstract

Osteoporosis is a common and important feature of rheumatoid disease which can be further influenced by the treatment administered. D-penicillamine, a lathyritic agent, can also theoretically hasten the osteoporotic process through its effect on collagen metabolism. In the present study the effects of the long-term second-line drugs D-penicillamine and oral gold (Auranofin) on bone density are presented. All the patients studied lost bone mineral over the 3-year period, but continuous D-penicillamine therapy for 1 year reversed this trend. Oral gold did not have the same effect. Measurements of bone density are an accurate indirect measurement of hand function, and there is a good correlation between hand function and the progress of osteoporosis. It is therefore suggested that treatment with D-penicillamine reverses the tendency to lose bone mineral improving synovitis, thus leading to improved hand function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401365

Source DB:  PubMed          Journal:  S Afr Med J


  4 in total

1.  Clinical assessment of disease activity in rheumatoid arthritis: evaluation of a functional test.

Authors:  A A Kalla; T J Kotze; O L Meyers; N D Parkyn
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

Review 2.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients.

Authors:  A A Kalla; O L Meyers; R Laubscher
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

4.  Tumour necrosis factor blockade and the risk of osteoporosis: back to the future.

Authors:  Philip Sambrook
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.